Biochemical and histopathological evidence for beneficial effects of Empagliflozin pretreatment on acetic acid-induced colitis in rats.
Empagliflozin預處理對乙酸誘導大鼠結腸炎的有益效果:生化和組織病理證據。
BMC Gastroenterol 2023-11-20
Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials.
成人和青少年慢性特發性蕁麻疹患者中利格利珠單抗的療效和安全性:兩項3期隨機對照試驗結果。
Lancet 2024-04-05
Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials.
Bimekizumab在中重度汗腺炎擴散性性膿瘡患者中的療效和安全性(BE HEARD I和BE HEARD II):兩項48週、隨機、雙盲、安慰劑對照、多中心3期試驗。
Lancet 2024-05-25
兩個第三階段試驗 BE HEARD I 和 II 證實 bimekizumab 對中重度汗腺炎患者有效且安全。與安慰劑相比,bimekizumab 顯著改善患者症狀,且應答率更高,持續至48週。不良事件輕微,無新安全問題。bimekizumab 耐受性佳,臨床效果顯著,適合治療汗腺炎患者。
PubMedDOI
Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease.
Risankizumab 對中重度克隆氏病與 Ustekinumab 的比較。
N Engl J Med 2024-07-17